Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics, Including Executive/Consultant Guides and Customized Forecasting/Analysis 2022 - 2026" report has been added to ResearchAndMarkets.com's offering.
Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created. And its not a small segment either.
It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.
A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.
The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.
Cancer Immuno-Oncology Diagnostics Recent Developments
OncoHost Expands Prophet Platform Research
Protein-Based Liquid Biopsy Panel Assesses TME
Oncimmune Announces Sixfold Revenue Increase
Mayo Clinic, Personalis Ink Collaboration
Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes
Qiagen, OncXerna Close Companion Dx Development Deal
Natera Test to Guide Therapy for Bladder Cancer
Veracyte Halio Acquisition to Boost Immuno-oncology Activity
Freenome Eyes New Dx Possibilities
Oncocyte Data has Potential as Immunotherapy Response Predictor
OncoDNA use HalioDx to Expand into North America
Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay
Qiagen Expands Immuno-Oncology Portfolio
Immune Profiling System Redirected to Fight COVID-19
IncellDx Awarded PD-L1 Detection Patent
FDA Approves CDx for Trastuzumab
Promega Nabs CE Mark for Microsatellite Instability IVD
ArcherDx partners with AstraZeneca for Immuno-Oncology
Germline Results Guides Precision Therapy
Agilent PD-L1 Assay Gets FDA Approval
Bayer, OrigiMed Form Companion Diagnostic Development Alliance
Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy123
SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures
Biocare Medical Launches 7 Novel IVD Antibodies
Oncocyte to Acquire Insight Genetics for $12M
Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
Generex to Merge with NuGenerex Immuno-Oncology
Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies
Hematogenix Launches FDA Approved Immuno-oncology Test for TripleNegative Breast Cancer
Icon Acquires MolecularMD
Profiles of Key Immuno-oncology Companies
10x Genomics, Inc.
Agena Bioscience, Inc.
Baylor Miraca Genetics Laboratories
Beckman Coulter Diagnostics
BGI Genomics Co. Ltd
Bio-Rad Laboratories, Inc.
Caris Molecular Diagnostics
Castle Biosciences, Inc.
Charles River Laboratories
Cytolumina Technologies Corp.
Datar Cancer Genetics Limited
FUJIFILM Wako Diagnostics
HTG Molecular Diagnostics
MDNA Life SCIENCES, Inc.
Menarini Silicon Biosystems
Myriad Genetics/Myriad RBM
Novogene Bioinformatics Technology Co., Ltd.
Ortho Clinical Diagnostics
Oxford Nanopore Technologies
Personal Genome Diagnostics
Roche Molecular Diagnostics
Singlera Genomics Inc.
Tempus Labs, Inc.
Thermo Fisher Scientific Inc.
Thrive Earlier Detection.
Factors Driving Growth
Factors Limiting Growth
Complex Role of Diagnostics
Clinical Trials Role
Diagnostic Technology Development
Combinations - Issues and Complexity
Shifting Role of Diagnostics
Multiplexing and Foundation One
The Disruption Dynamic
The Race for Biomarkers
The Next Five Years
Immunotherapy - Guide to Immune Technologies
Innate immune system
Natural killer cells
Adaptive immune system
Killer T cells
Helper T cells
Gamma delta T cells
B lymphocytes and antibodies
Tumor immunology - the immune surveillance system
Immuno Oncology Diagnostics
Players in a Dynamic Market
Academic Research Lab
Diagnostic Test Developer
Genomic Instrumentation Supplier
Cell Separation and Viewing Instrumentation Supplier
Independent Testing Lab
Public National/regional lab
For more information about this report visit https://www.researchandmarkets.com/r/qqizi6
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900